Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
ImmunGene, Inc. today announced that it has regained development rights to three of its antibody-interferon fusion product candidates, IGN001,...
ImmunGene, Inc., a biotechnology company focused on developing antibody-cytokine fusion technology therapies to treat cancer, today announced it has...
ImmunGene, Inc. today announced that pre‑clinical studies of its novel anti‑CD20 antibody-interferon alpha fusion protein, IGN002, demonstrated...
ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today that a profile of the company...
ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today it has entered into a...
ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics with numerous anti-cancer functions built into a ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.